Daily Respiratory Research Analysis
Analyzed 163 papers and selected 3 impactful papers.
Summary
A phase 3 randomized trial (ZEAL-1L) found that adding niraparib to pembrolizumab as maintenance therapy did not improve outcomes in advanced/metastatic NSCLC. A multi-center target trial emulation in fibrotic ILD showed mycophenolate or azathioprine did not improve 3-year transplant-free survival and was linked to higher mortality in some subtypes. A Bayesian network meta-analysis in unresectable stage III EGFR-mutated NSCLC identified CRT plus EGFR-TKI as optimal for OS, while EGFR-TKI with radiotherapy ranked best for PFS and tolerability.
Research Themes
- Negative phase 3 oncology trial informing de-implementation of ineffective maintenance strategies
- Causal-inference emulation challenging immunosuppression in fibrotic ILD
- Evidence synthesis guiding stage III EGFR-mutant NSCLC multimodality therapy
Selected Articles
1. Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).
In this double-blind phase 3 maintenance trial in advanced/metastatic NSCLC (n=666 ITT), niraparib added to pembrolizumab did not improve PFS (median 5.55 months both arms; HR 1.00) and key secondary endpoints were not formally tested. Grade ≥3 treatment-related adverse events were mainly hematologic (anemia, thrombocytopenia, neutropenia), with no new safety signals.
Impact: A negative, well-conducted phase 3 RCT immediately informs practice by discouraging an ineffective maintenance approach, preventing exposure to added hematologic toxicity and cost without benefit.
Clinical Implications: Maintenance niraparib should not be added to pembrolizumab after chemo-immunotherapy response in advanced NSCLC outside clinical trials. Clinicians should avoid this combination and consider alternative evidence-based maintenance strategies or observation.
Key Findings
- No PFS improvement: median 5.55 months in both niraparib+pembrolizumab and placebo+pembrolizumab arms (HR 1.00, 95% CI 0.79–1.27).
- Key secondary endpoints (PFS in ITT, OS, CNS progression) were not formally tested due to hierarchy stop.
- Grade ≥3 treatment-related AEs were mainly hematologic (anemia, thrombocytopenia, neutropenia); no new safety signals.
Methodological Strengths
- Randomized, double-blind, placebo-controlled phase 3 design with blinded independent central review of PFS.
- Large ITT population (n=666) with prespecified hierarchical testing.
Limitations
- Negative primary endpoint halted formal testing of key secondaries, limiting definitive conclusions on OS and CNS outcomes.
- Lack of biomarker-stratified efficacy signals in the abstract; potential heterogeneity in prior therapy exposure not detailed.
Future Directions: Focus on biomarker-enriched maintenance strategies, alternative PARP inhibitor/ICI sequencing, and exploration of subgroups (e.g., HRR-deficient) where synergy could exist.
INTRODUCTION: This randomized, double-blind, phase 3 study evaluated niraparib-plus-pembrolizumab as maintenance therapy for patients with advanced/metastatic non-small cell lung cancer (NSCLC; ZEAL-1L, ClinicalTrials.gov identifier: NCT04475939). METHODS: Adults with advanced/metastatic squamous/nonsquamous NSCLC without known targetable driver alteration were randomly assigned (1:1) to receive niraparib-plus-pembrolizumab or placebo-plus-pembrolizumab as maintenance therapy. Niraparib was given as a daily oral dose of 300 mg, and intravenous pembrolizumab was administered at 200 mg every 3 weeks. The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) in patients with complete or partial response (CR/PR) to front-line chemotherapy combined with pembrolizumab. Hierarchical testing was performed on the primary and key secondary endpoints in a prespecified sequential order; formal testing was stopped if any endpoint failed to reach statistical significance. RESULTS: Patients comprising the intent-to-treat (ITT) population (n=666) were randomly assigned to niraparib-plus-pembrolizumab (n=331) or placebo-plus-pembrolizumab (n=335) therapy. The median PFS for the CR/PR population (n=200 receiving niraparib-plus-pembrolizumab; n=201 receiving placebo-plus-pembrolizumab) was 5.55 months for both treatment arms (hazard ratio [HR], 1.00; 95% CI, 0.79-1.27; 1-sided p=0.502). Key secondary endpoints of PFS by BICR in the ITT population, overall survival in CR/PR and ITT populations, and time to progression in the central nervous system were not formally tested. The most common grade ≥3 treatment-related adverse events for the niraparib-plus-pembrolizumab arm were hematologic (anemia, thrombocytopenia, and neutropenia). CONCLUSION: The addition of niraparib to pembrolizumab for maintenance therapy in patients with advanced/metastatic NSCLC did not result in improved efficacy; no new safety signals were detected. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT04475939.
2. Mycophenolate and Azathioprine in Fibrotic Interstitial Lung Disease.
Using a rigorous target trial emulation across 2,270 fibrotic ILD patients, initiation of mycophenolate or azathioprine within 6 months did not improve 3-year transplant-free survival or lung function and was associated with higher mortality in non-IPF IIP and fibrotic HP. Findings challenge routine immunosuppression in these subtypes and support prospective RCTs.
Impact: This large, methodologically advanced causal-inference study directly informs practice by questioning widely used immunosuppression in non-IPF fibrotic ILD and identifying subtypes with potential harm.
Clinical Implications: Avoid routine initiation of mycophenolate or azathioprine in non-IPF IIP and fibrotic HP without strong individualized indications; discuss potential harm. Prioritize enrollment in RCTs and consider antifibrotics and antigen avoidance where appropriate.
Key Findings
- Immunosuppression did not improve 3-year transplant-free survival across fibrotic ILD subtypes.
- Higher mortality associated with immunosuppression in non-IPF IIP (HR 1.38) and fibrotic HP (HR 1.62).
- No differential effect on lung function trajectory with immunosuppression in any subtype.
Methodological Strengths
- Target trial emulation using clone–censor–weighting with stabilized IPTW to reduce immortal time and selection bias.
- Large, multi-center cohort with stratified analyses across ILD subtypes and weighted GEE for lung function.
Limitations
- Observational emulation susceptible to residual confounding and misclassification of indications.
- Heterogeneity in dosing, duration, and co-treatments not fully standardized.
Future Directions: Prospective, subtype-specific RCTs comparing immunosuppression versus antifibrotics or combination strategies; biomarker-driven selection to identify responders or harm-prone groups.
RATIONALE: Immunosuppression is routinely used for non-idiopathic pulmonary fibrosis (IPF) interstitial lung diseases (ILDs), despite limited trial evidence and unclear impact on long-term outcomes. OBJECTIVES: To evaluate whether mycophenolate or azathioprine improves three-year transplant-free survival and lung function trajectory in fibrotic ILD, including non-IPF idiopathic interstitial pneumonia (IIP), fibrotic hypersensitivity pneumonitis (fHP), and connective-tissue disease (CTD) associated ILD. METHODS: We employed a clone-censor-weighting framework to emulate a randomized controlled trial in this multi-center retrospective study. Each patient was cloned and assigned to immunosuppression initiation within 6 months of enrollment or no initiation strategies, and censored when the assigned strategy deviated from observed treatment. Stabilized inverse probability treatment and censoring weights were used. MEASUREMENTS: The primary endpoint was three-year transplant-free survival assessed with weighted Cox models across treatment strategies. Weighted generalized estimating equations were used to model lung function trajectory. MAIN RESULTS: Among 2,270 included patients, 18% (186/1022) with non-IPF IIP, 30% (162/544) with fHP, and 31% (221/704) with CTD-ILD were initiated on immunosuppression within 6-months. Immunosuppression was not associated with improved survival within any ILD subtype but was associated with worse survival in non-IPF IIP (HR 1.38, 95% CI 1.04-1.84) and fHP (HR 1.62, 95% CI 1.09-2.40). Immunosuppression was not associated with differential lung function trajectory within any ILD subtype. CONCLUSIONS: In this study, immunosuppression initiation showed no evidence of benefit for three-year transplant-free survival or lung function and was associated with higher mortality in select fibrotic ILD subtypes. Prospective randomized controlled trials are needed to inform patient care.
3. Optimal treatment strategies for unresectable stage III
This Bayesian network meta-analysis (12 studies; n=1,529) found that CRT followed by EGFR-TKI significantly improved OS versus CRT alone (HR 0.63). EGFR-TKI integrated with radiotherapy ranked best for PFS (HR 0.14) with the lowest severe radiation pneumonitis risk. CRT+durvalumab did not achieve survival benefit and showed higher toxicity in EGFR-mutant stage III disease.
Impact: Provides comparative effectiveness evidence to redefine standard-of-care for EGFR-mutant unresectable stage III NSCLC, prioritizing CRT+EGFR-TKI and supporting chemo-free EGFR-TKI+RT for PFS and tolerability.
Clinical Implications: For EGFR-mutant unresectable stage III NSCLC, consider CRT followed by EGFR-TKI to optimize OS; EGFR-TKI+RT (without chemotherapy) may be preferred when PFS and tolerability are prioritized. CRT+durvalumab may be less favorable in this genotype.
Key Findings
- CRT+EGFR-TKI improved OS versus CRT alone (HR 0.63; 95% CrI 0.41–0.94) and achieved the highest ORR.
- EGFR-TKI+RT ranked first for PFS (HR 0.14; 95% CrI 0.06–0.33) with the lowest severe radiation pneumonitis risk.
- CRT+durvalumab did not yield survival benefit (PFS HR 0.75; OS HR 0.82) and had higher toxicity; RCT-only sensitivity supported PFS advantage of TKI-based strategies.
Methodological Strengths
- Prospero-registered systematic search across four databases with Bayesian random-effects NMA.
- Sensitivity analysis restricted to RCTs confirmed robustness of PFS findings.
Limitations
- Inclusion of retrospective studies may introduce bias; indirect comparisons and heterogeneity across regimens and sequencing.
- Genotype (EGFR mutation subtype) and radiotherapy technique heterogeneity may affect generalizability.
Future Directions: Head-to-head RCTs comparing CRT+EGFR-TKI versus CRT+durvalumab in EGFR-mutant disease; trials optimizing sequencing (induction/concurrent/consolidation) and integrating toxicity mitigation.
BACKGROUND: The PACIFIC regimen (consolidation durvalumab following chemoradiotherapy) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). With the publication of data from the phase III LAURA trial and the emergence of real-world evidence regarding sequential toxicity, concurrent chemoradiotherapy followed by sequential targeted therapy with EGFR tyrosine kinase inhibitors (TKIs) is recommended for patients with EGFR mutations. However, the optimal combination regimen remains to be determined. METHODS: We systematically searched the PubMed, Embase, Cochrane Library, and Web of Science databases to identify randomized controlled trials (RCTs) and high-quality retrospective studies comparing various therapeutic strategies for unresectable stage III EGFR-mutated NSCLC. The primary endpoints were progression-free survival (PFS) and overall survival (OS), while secondary endpoints included the objective response rate (ORR) and safety profiles. A network meta-analysis (NMA) was performed using a Bayesian random-effects model. Hazard ratios (HRs), odds ratios (ORs), and their corresponding 95% credible intervals (CrIs) were calculated. RESULTS: A total of 12 studies involving 1,529 patients were analyzed to compare six therapeutic strategies: consolidation durvalumab following chemoradiotherapy (CRT+Durva), CRT alone, consolidation EGFR-TKIs after CRT (CRT+EGFR-TKI), EGFR-TKI monotherapy, EGFR-TKI in combination with chemotherapy (EGFR-TKI+Chemo), and EGFR-TKI integrated with radiotherapy (EGFR-TKI+RT) via induction, concurrent, or consolidation sequencing. NMA revealed that CRT+EGFR-TKI was the only strategy to demonstrate a statistically significant improvement in OS compared to CRT alone (HR = 0.63, 95% CrI: 0.41-0.94), while also achieving the highest ORR. EGFR-TKI+RT (chemotherapy-free regimen) ranked first for PFS (HR = 0.14, 95% CrI: 0.06-0.33) and exhibited a favorable safety profile, associated with the lowest risk of severe radiation pneumonitis (RP). Notably, CRT+Durva failed to yield a survival benefit (PFS: HR = 0.75; OS: HR = 0.82) and was characterized by higher toxicity. An RCT-only sensitivity analysis demonstrated consistent PFS benefits and a comparable OS trend (HR = 0.68, 95% CrI: 0.33-1.4), validating the integration of real-world data to maintain adequate statistical power. CONCLUSIONS: For unresectable stage III EGFR-mutated NSCLC, CRT+EGFR-TKI represents the optimal strategy for extending OS. Conversely, the EGFR-TKI+RT (chemotherapy-free regimen) approach provides a superior balance between prolonged PFS and clinical tolerability. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420261285935.